Comment on

• Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

  Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. Rijal S, et al. Clin Infect Dis. 2013 Jun;56(11):1530-8. doi: 10.1093/cid/cit102. Epub 2013 Feb 20. Clin Infect Dis. 2013. PMID: 23425958
• Multilocus parasite gene polymorphism and/or parasite-selected mutations in host genome may discriminate between relapse and reinfection in the failure of miltefosine treatment in visceral leishmaniasis.

  Das S. Das S. Clin Infect Dis. 2013 Nov;57(9):1364-5. doi: 10.1093/cid/cit506. Epub 2013 Aug 13. Clin Infect Dis. 2013. PMID: 23943819 No abstract available.